Announcements Trials
Browse Landscape

Phase

Phase 2 126Phase NA 110Phase 1 54Phase 3 29Phase 1/2 27Phase EARLY_PHASE1 10Phase 4 4Phase 2/3 3

Status

Completed 56Recruiting 27Unknown 18Terminated 11Active not recruiting 10Not yet recruiting 6Withdrawn 3Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 15Head & Neck 5Breast 4Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Dermatologic 3Sarcoma 2Gynecologic 2CNS 2Thoracic 1Other neoplasm 1Myeloid 1

Conditions

Prostatic Neoplasms 2Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2Tacrolimus 1Sirolimus 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Genitourinary × Clear all
NCT07084909 2025-12-10

HARRIER

Lantheus Medical Imaging

Phase 2/3 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03800784 2021-12-15

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡